Horizon Therapeutics Public Limited Company provided earnings guidance for the full-year 2022. For the period, the company now expects full-year 2022 net sales to range between $3.53 billion and $3.60 billion, updated from the previous guidance range of $3.9 billion to $4.0 billion.
Horizon Therapeutics Public Limited Company
Equities
HZNP
IE00BQPVQZ61
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+26.18% | 661B | |
+26.74% | 566B | |
-6.78% | 352B | |
+19.42% | 332B | |
+3.48% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.47% | 145B |